Fr1da Early Diagnosis and Care of Type 1 Diabetes
Launched by HELMHOLTZ ZENTRUM MÜNCHEN · Jul 30, 2019
Trial Information
Current as of April 25, 2025
Recruiting
Keywords
ClinConnect Summary
The Fr1da study is looking at how we can find and treat type 1 diabetes earlier in young people living in Bavaria. The goal is to see if early detection helps prevent serious health issues that can happen when diabetes first shows up, and if it also helps reduce stress for families through education and support. This study is currently recruiting participants, specifically children aged 2 to 18 years, as long as one parent gives their permission.
If your child is eligible and takes part in the study, they'll have the chance to receive early care and support related to type 1 diabetes. This could mean better health outcomes and less worry for both the child and the family. It's a great opportunity to be part of important research that could improve how we manage diabetes in the future!
Gender
ALL
Eligibility criteria
- • written informed consent by one custodial parent
About Helmholtz Zentrum München
Helmholtz Zentrum München is a leading research institution dedicated to advancing health and environmental sciences. As a member of the Helmholtz Association, it focuses on innovative biomedical research, emphasizing the interplay between genetics, environmental factors, and lifestyle in relation to human health. The center is committed to translating scientific discoveries into clinical applications, driving progress in disease prevention and treatment. Through collaborative efforts and state-of-the-art facilities, Helmholtz Zentrum München plays a pivotal role in fostering cutting-edge clinical trials aimed at improving patient outcomes and enhancing public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials